Extended Data Fig. 5: PARP11 undermines tumoricidal activities of CAR T cells.
From: Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors
a Proliferation of CD19-BBz CAR T cells prepared from WT or Parp11−/− mouse splenic T cells. Data are shown as mean ± SEM (n = 5 samples for each group). Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test. ns, P = 0.6599. b Flow cytometry analysis of CAR expression in mouse T cells of indicated genotypes after Meso–BBz transduction. c Representative flow cytometry analysis of CAR expression in mouse T cells of indicated genotypes after CD19-BBz transduction. d Weight of hCD19-B16F10 s.c. tumors that grew in NSG mice treated with PBS (Control) or adoptively transferred with CD19-BBz CAR T cells (1 × 106/ mouse, i.v) of indicated genotypes as in Fig. 7d. Data are shown as mean ± SEM (n = 5 mice for each group). Statistical analysis was performed using ordinary one-way ANOVA with Tukey’s multiple comparisons test. **P = 0.0087, ****P < 0.0001, *P = 0.0175. e Cell surface expression of human CD19 on the surface of hCD19-B16F10 malignant cells is checked by flow cytometry. Data are shown as mean ± SEM (n = 5 mice for each group). Statistical analysis was performed using ordinary one-way ANOVA with Tukey’s multiple comparisons test. f Expression of TIM-3, PD-1 and LAG-3 exhaustion markers by WT or Parp11−/− CAR T cells isolated from hCD19-B16 subcutaneous tumors from mice described in Extended Data Fig. 5d. Data are shown as mean ± SEM (n = 5 mice for each group). Statistical analysis was performed using ordinary one-way ANOVA with Tukey’s multiple comparisons test. **P = 0.0270. g Numbers of WT or Parp11−/− CAR T cells in the blood, spleen or hCD19-B16 subcutaneous tumors from mice described in Extended Data Fig. 5d. Data are shown as mean ± SEM (n = 5 mice for each group). Statistical analysis was performed using ordinary one-way ANOVA with Tukey’s multiple comparisons test. **P = 0.0038, *P = 0.0212.
